The International Society of Heart and Lung Transplantation (ISHLT) 44th Annual Meeting is April 10-13 in Prague. Baylor Scott & White researchers will present the latest insights to better serve patients with end-stage heart and lung disease.

Our Dallas lung transplant team includes world-renowned experts in thoracic surgery and pulmonary medicine.

Investigators at Baylor Scott & White Research Institute and clinicians on the medical staff at Baylor Scott & White All Saints Medical Center – Fort Worth, Baylor Scott & White Heart and Vascular Hospital, Baylor Scott & White Medical Center – Temple Baylor Scott & White The Heart Hospital – Plano and Baylor University Medical Center in Dallas will be involved in ​39 presentations, scheduled talks and panel discussions.

Additional details about the annual meeting are on the event website.

FEATURED PRESENTATIONS AND SESSIONS HIGHLIGHTING HEART AND LUNG TRANSPLANT RESEARCH

TUESDAY, APRIL 9, 2024

ORAL SESSION: Donor Selection/DCD: Expanding the Donor Pool – A Cardiologist's POV

ORAL SESSION: Antibody Mediated Rejection: From Simple to Complex

WEDNESDAY, APRIL 10, 2024

ORAL SESSION: Real-World Clinical Outcomes of DCD Heart Transplantation from the OCS Heart Perfusion (OHP) Registry: Benchmarking to Other Preservation Methods

  • Research collaborator: Dan Meyer, MD

  • Time: 3:30-3:40 p.m. CEST

  • Abstract/Study Purpose: This report evaluates characteristics and clinical outcomes of DCD heart transplants using OCS Heart System to concurrent DCD heart transplants using other methods of reperfusion/preservation at the same US institutions.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/3961

ORAL SESSION: Clinical Outcomes Among Impella 5.0/5.5 Recipients with Cardiogenic Shock: A Report from The Cardiogenic Shock Working Group

  • Research collaborator: Jaime Hernandez-Montfort, MD, MPH, MSc

  • Time: 4:30-4:40 p.m. CEST

  • Abstract/Study Purpose: The Impella 5.0 and 5.5 are large-bore trans-valvular mechanical circulatory support devices (MCSD) used in patients with cardiogenic shock (CS). Real world data evaluating clinical outcomes in patients supported with Impella 5.0/5.5 remain limited by small numbers or single center series.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/407

ORAL SESSION: The Trifecta-Heart Study: Comparing Plasma Donor-Derived Cell-Free DNA to Gene Expression in Endomyocardial Biopsies and a Comparison to Results in Kidney Transplant

  • Research collaborator: Timothy Gong, MD

  • Time: 4:30-4:40 p.m. CEST

  • Abstract/Study Purpose: Trifecta-Heart (ClinicalTrials.gov # NCT04707872) is an investigator-initiated prospective trial to compare dd-cfDNA to genome-wide molecular changes in endomyocardial biopsies (EMBs). We report the results of the first phase of the Trifecta-Heart study conducted at 4 vanguard centers, including comparisons with findings in kidney transplants in Trifecta-Kidney (ClinicalTrials.gov # NCT04239703).

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/4158

ORAL SESSION: Acute Limb Ischemia is an Important Target of Therapy to Decrease In-Hospital Mortality and is Associated with Endovascular Acute Mechanical Circulatory Support in Cardiogenic Shock

  • Research collaborator: Jaime Hernandez-Montfort, MD, MPH, MSc

  • Time: 5-5:10 p.m. CEST

  • Abstract/Study Purpose: Acute limb ischemia (ALI) is a devastating complication of cardiogenic shock (CS) Real world data evaluating outcomes of ALI in CS remain limited.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/4077

ORAL SESSION: Clinical Outcomes with Intra-Aortic Balloon Pump in Cardiogenic Shock Due to Acute Myocardial Infarction or Heart Failure: A Report from the Cardiogenic Shock Working Group

  • Research collaborator: Jaime Hernandez Montfort, MD, MPH, MSc

  • Time: 5:15-5:25 p.m. CEST

  • Abstract/Study Purpose: Intra-aortic balloon pumps (IABPs) are the most used mechanical circulatory support devices (MCSD) in patients with cardiogenic shock (CS) in US. Real world data evaluating clinical outcomes in patients supported with IABP remain limited by small numbers. Moreover, there is lack of correlation of outcomes for the use of IABP in CS due to acute myocardial infarction (MI-CS) vs heart failure (HF-CS).

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/4078

ORAL SESSION: Genome-Wide Molecular Analysis of Heart Transplant Endomyocardial Biopsies Separately Analyzing Rejection and Parenchymal Injury

  • Research collaborator: Shelley Hall, MD

  • Time: 5:15-5:25 p.m. CEST

  • Abstract/Study Purpose: The Molecular Microscope® Diagnostic System (MMDx) system for interpreting heart transplant endomyocardial biopsies (EMBs) currently uses expression of kidney-derived rejection-associated transcripts (RATs) to identify antibody-mediated and T cell-mediated rejection (ABMR, TCMR), but this also detects recent acute injury. We developed a new model to assess rejection and injury separately.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/4162

POSTER: Association Between Pre-Transplant Mechanical Circulatory Support Status and Donor-Derived Cell-Free DNA Levels and Gene Expression Profiling Following Heart Transplant

  • Research collaborator: Shelley Hall, MD

  • Time: 6-7 p.m. CEST

  • Abstract/Study Purpose: The goal of this analysis was to assess the relationship between pre-transplant short-, medium- or long-term mechanical circulatory support (MCS) status and donor-derived cell-free DNA (dd-cfDNA; AlloSure, CareDx) levels plus gene expression profiling (GEP; AlloMap, CareDx) scores in the first 3- and 12-months following heart transplantation (HT) using data from the Surveillance HeartCare Outcomes Registry (SHORE).

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/session/382

POSTER: Temporal Trends of Vasopressor and Inotrope Use in Cardiogenic Shock: A Cardiogenic Shock Working Group Report

  • Research collaborator: Jaime Hernandez-Montfort, MD, MPH, MSc

  • Time: 6-7 p.m. CEST

  • Abstract/Study Purpose: There remains a paucity of the temporal use and total vasoactive medication requirements for cardiogenic shock (CS) patients in the contemporary era.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/5555

POSTER: Impact of Cumulative Vasopressor and Inotrope Medications on Outcomes in Cardiogenic Shock: A Cardiogenic Shock Working Group Report

  • Research collaborator: Jaime Hernandez-Montfort, MD, MPH, MSc

  • Time: 6-7 p.m. CEST

  • Abstract/Study Purpose: There is a paucity of data on the prognostic implication of vasoactive medications on mortality in cardiogenic shock (CS).

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/5556

THURSDAY, APRIL 11, 2024

POSTER: Transitions Between Molecular Rejection Classes In Heart Endomyocardial Biopsies

POSTER: Comparative regional analysis of severe Primary Graft Dysfunction: Insights from the International Consortium on PGD

POSTER: Adjunctive Cytogam And CMV Insight T-cell Immunity Assay For Refractory CMV Disease In Heart Transplant Recipients - Single-center Case Series Of Challenging Cases

  • Research collaborator: Melina De Oliveira Valdo Giugni, MD

  • Time: 4:30-5:30 p.m. CEST

  • Abstract/Study Purpose: Refractory CMV disease portends a poor prognosis after orthotopic heart transplant (OHT). Genotyping CMV to detect antiviral resistance mutations in UL97 and UL54 genes is recommended. There are off-label antiviral drugs and adjunctive therapies used for treatment of resistant CMV, but with limited evidence. Here we describe our experience with the adjunctive use of Cytomegalovirus Immune Globulin Intravenous [Human] (CytoGam) with antiviral drugs in 2 high-risk D+/R- CMV mismatch patients with refractory CMV disease.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/6079

POSTER: Outcomes in Patients with Acute Cellular Rejection Grade 1R: Is the Debate Over?

  • Research collaborator: Jaime Hernandez-Montfort, MD, MPH, MSc

  • Time: 4:30-5:30 p.m. CEST

  • Abstract/Study Purpose: Acute Cellular Rejection (ACR) grade 1R is usually untreated; however, recurrent 1Rs are associated with negative long-term outcomes. Donor-derived cell-free DNA (dd-cfDNA) is a biomarker for heart allograft injury and rejection. We hypothesize that ACR 1R concurrent with elevated dd-cfDNA may be indicative of clinically relevant rejection. We analyzed outcomes in an interim sub-analysis of patients with ACR 1R enrolled in the multicenter Prospera Test Evaluation in Cardiac Transplant (ProTECT) study, a registry of adult heart transplant (HTx) recipients in the US undergoing dd-cfDNA monitoring with the Prospera™ test (Natera, Austin, TX).

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/5889

POSTER: The Role of Multimodal Imaging in Guiding Myocardial Recovery: A Case of LVAD Explantation Following Concurrent Lymphocytic and COVID-19 Myocarditis

  • Research collaborator: Amarinder Bindra, MD

  • Time: 4:30-5:30 p.m. CEST

  • Abstract/Study Purpose: This case study showcases the role of multimodal imaging in demystifying complex cardiac conditions and guiding myocardial recovery processes.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/5897

POSTER: Thoracic Organ Perfusion (TOP) Registry Annual Report - More Than 350 OCS Lung Transplants in the US

  • Research collaborator: Gary Schwartz, MD, Todd Grazia, MD

  • Time: 4:30-5:30 p.m.

  • Abstract/Study Purpose: TOP registry is an all-inclusive registry established to collect donor/recipient and post-transplant clinical outcomes on all OCS Lung transplants in the real world in the US.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/5980

POSTER: Mitigating Risk Using the Primary Graft Dysfunction-Artificial Intelligence (PGD-AI) Calculator in a Contemporary Toronto Cohort: An Analysis from the International Consortium on PGD

ORAL SESSION: Clinical Outcomes and the Impact of SCAI Stage Among Protekduo Right Ventricular Assist Device Recipients with Cardiogenic Shock: A Report from the Cardiogenic Shock Working Group

  • Research collaborator: Jaime Hernandez-Montfort, MD, MPH, MSc

  • Time: 4:42-4:46 p.m. CEST

  • Abstract/Study Purpose: The ProtekDuo is a dual-lumen cannula used to provide mechanical circulatory support (MCS) for right heart failure (RHF) in patients with cardiogenic shock (CS). It can be used for primary RHF or in those with biventricular failure, concomitant with an LV support device. Real world data evaluating outcomes in patients supported with the ProtekDuo remain limited by small numbers and a lack of correlation with outcomes.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/4082

ORAL SESSION: Organ Care System Heart Perfusion (OHP) Registry Annual Report - Donation After Circulatory Death Heart Transplant Outcomes

  • Research collaborator: Dan Meyer, MD

  • Time: 5-5:04 p.m. CEST

  • Abstract/Study Purpose: Following FDA approval of the Organ Care Heart Perfusion System (OCS) for donation after cardiac death (DCD) heart transplants in the US, the OHP registry was initiated in April 2022. We are reporting donor/recipient characteristics and early clinical outcomes of the DCD heart transplant cohort from the OHP Registry.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/4095

ORAL SESSION: Practice Variation in Temporary MCS Device Choice in Cardiogenic Shock

  • Research collaborator: Jaime Hernandez-Montfort, MD, MPH, MSc

  • Time: 5:06-5:10 p.m. CEST

  • Abstract/Study Purpose: Evidence guiding the choice of temporary MCS in cardiogenic shock (CS) is limited, potentially leading to practice variation. This study aims to quantify the degree of initial MCS device choice variation in CS and identify associated factors.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/4086

FRIDAY, APRIL 12, 2024

ORAL SESSION: Forget the Biopsy: Screen All with Blood Testing

ORAL SESSION: Updates from the International Consortium on Primary Graft Dysfunction: An Interim Report and Important Themes

  • Presenter: Shelley Hall, MD

  • Time: 10-10:10 a.m. CEST

  • Abstract/Study Purpose: In 2021, we presented the first report from the International Consortium on Primary Graft Dysfunction (PGD) inclusive of 2476 patients from 10 centers. Herein, we present an updated interim analysis and highlight key themes that have emerged from this multicenter collaboration.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/3965

ORAL SESSION: Incidence and Risk Factors for Early Stroke Following Durable Left Ventricular Assist Device (LVAD) Implantation: An STS Intermacs Analysis

  • Research collaborator: Dan Meyer, MD

  • Time: 10:30-10:40 a.m. CEST

  • Abstract/Study Purpose: Stroke remains a devastating complication of durable LVAD therapy. Pre-implant patient factors have traditionally been used to predict the risk of post-implant stroke. The purpose of this study was to evaluate the incidence and risk factors for early stroke within 7 days following LVAD implantation with particular attention to the impact of intraoperative variables.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/4071

ORAL SESSION: Improved 2-Year Heart Transplant Survival with Moderate Hypothermic Donor Heart Preservation in the Guardian Heart Registry

  • Research collaborator: Dan Meyer, MD

  • Time: 10:45-10:55 a.m. CEST

  • Abstract/Study Purpose: Use of advanced moderate hypothermic donor heart preservation is increasing due to reports of consistently strong post-transplant outcomes. Approximately half of all DBD donor hearts in the US in 2023 have been transported in a Paragonix SherpaPak Cardiac Transport System (SCTS). The GUARDIAN Heart Registry, the largest global registry studying effects of static cold preservation, provides data to evaluate real-world benefits of using SCTS compared to conventional ice storage.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/3964

SPECIAL SESSION: Translating Registry Data to the Bedside (IMACS to CSWG to Temple)

POSTER: Shifting Strategies: Heart Transplant as a Bridge to Chemotherapy in Cardiac Al Amyloidosis

  • Author: Ossama Abou Hassan, MD

  • Time: 4:30-5:30 p.m. CEST

  • Abstract/Study Purpose: More than 50% of individuals with AL have heart involvement, which constitutes the most concerning prognostic risk. Advanced cardiac amyloidosis (CA) patients frequently may not have access to curative medications like high-dose chemotherapy and autologous stem cell transplantation (ASCT). Heart transplantation (HTx) may be an appropriate stepwise strategy to ensure long-term survival and serve as a bridge to additional therapy. Careful patient selection and risk stratification are crucial.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/6277

POSTER: Stability of True Left Ventricular Wireless Endocardial Receiver-Eelectrodeis Compatible with Safe Impella Bridge – A Case Report

  • Author: Melina De Oliveira Valdo Giugni, MD

  • Time: 4:30-5:30 p.m. CEST

  • Abstract/Study Purpose: CRT is most commonly performed indirectly by placing a "LV" lead in the coronary sinus. When adequate biventricular pacing cannot be achieved, the Wireless Stimulation Endocardially (WiSE) CRT system (EBR Systems, Sunnyvale, CA) is an investigational option that utilizes a true left ventricular endocardial receiver-electrode (R-E). A reported risk of the method is insufficient anchoring with risk of embolization. In the absence of any previous report of pLVAD in patients with Wise CRT system, medical necessity prompted balance of risk and benefit. We report a successful implant of an Impella pLVAD (Abiomed Inc., Danvers, MA) in a patient with previous implant of WiSE CRT system.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/6321

POSTER: Improved Post-Transplant Outcomes in Blood Group O Recipients Through Controlled Hypothermic Preservation

  • Research collaborator: Dan Meyer, MD

  • Time: 4:30-5:30 p.m. CEST

  • Abstract/Study Purpose: Organs from blood type O donors can go to a recipient with any blood type, but recipients with blood type O are limited to receiving type O donor hearts. Consequently, type O recipients tend to wait longer for a heart, increasing the opportunity to worsen prior to transplant, and studies have shown higher post-transplant mortality in Type O recipients. We evaluated outcomes from recipients in GUARDIAN Heart stratified by blood type to assess impact on post-transplant outcomes.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/6345

POSTER: Long Term Functional Outcomes in Patients with Covid-19 Requiring Extracorporeal Membranous Oxygenation Support

  • Research collaborator: John Eisenga, MD

  • Time: 4:30-5:30 p.m. CEST

  • Abstract/Study Purpose: Although patients treated with extracorporeal membranous oxygenation (ECMO) can have reduced long-term lung function, impaired quality of life, and high rates of PTSD, data on patients with severe COVID-19 requiring ECMO support are limited. We undertook a prospective study of our post-COVID ECMO population assessing patient clinical data, quality of life metrics, and PTSD.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/6405

POSTER: The Impact of Early Readmission on Patient Functional Status Following Left Ventricular Assist Device Implantation

  • Author: John Eisenga, MD

  • Time: 4:30-5:30 p.m. CEST

  • Abstract/Study Purpose: While left ventricular assist device (LVAD) implantation has been shown to improve both survival and quality of life in patients with end stage heart failure, these patients have a high rate of hospital readmissions. The impact of early readmissions on functional status is not currently known. We undertook a retrospective analysis to investigate the impact of early readmissions following LVAD implant on future functional status.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/6406

POSTER: Successful Management of Mycotic Visceral Aneurysms in a LVAD Patient: Navigating Postoperative Challenges

  • Author: Kendall Wermine, MD

  • Time: 4:30-5:30 p.m. CEST

  • Abstract/Study Purpose: Left ventricular assist devices (LVADs) are indispensable therapeutic tools that improve survival and quality of life in patients with advanced heart failure. In this case report, we present a unique case of the surgical management of concurrent mycotic SMA and splenic aneurysms secondary to disseminated Candida Albicans infection. It highlights the multifaceted nature of caring for LVAD-dependent patients and the intricacies that can emerge.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/6415

POSTER: Clinician assessed versus objective measures of frailty in patients

  • Research collaborator: Aditi Nayak, MD

  • Time: 4:30-5:30 p.m. CEST

  • Abstract/Study Purpose: Society guidelines recommend frailty assessment in Left Ventricular Assist Device (LVAD) candidates. Frailty is a multi-domain syndrome that includes compromised mobility and nutritional status. While often assessed via the "eyeball test," there is a need to identify objective frailty measures that correlate with patient outcomes, allowing for standardization of candidacy assessment. We studied 1) the association of clinician assessed frailty with objective measures of mobility (6-minute walk distance, 6MWD) and nutritional status (prealbumin), and 2) the association of these factors with outcomes.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/6191

ORAL PRESENTATION: Determination of the Optimal Temperature for Organ Preservation through Analysis of the Guardian Registry

  • Research collaborator: Dan Meyer, MD

  • Time: 4:42-4:46 p.m. CEST

  • Abstract/Study Purpose: Controlled moderate hypothermia using the Paragonix SherpaPak Cardiac Transport System (STS) has been shown to result in significant improvements in post-transplant outcomes especially those related to severe primary graft dysfunction (PGD) and right ventricular dysfunction (RVD). However, there are limited data available describing the upper and lower bounds around the ideal temperature. We sought to stratify the post-transplant outcomes by temperature as observed in the GUARDIAN Heart Registry.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/4911

ORAL PRESENTATION: Reduced Risk of Cardiovascular-Related Death Associated with Moderate Hypothermic Donor Heart Preservation in the Guardian Heart Registry

  • Research collaborator: Dan Meyer, MD

  • Time: 4:54-4:58 p.m. CEST

  • Abstract/Study Purpose: Donor hearts are often transported using an ice cooler, despite ISHLT recommendations of 4 to 10°C due to known risks of freezing injury and risk of primary graft dysfunction (PGD). The Paragonix SherpaPak Cardiac Transport System (SCTS) is an advanced donor heart preservation system which maintains organ temperatures between 4 - 8°C. Real-world evidence of using SCTS compared to ice storage has been shown to significantly reduce severe PGD in the global GUARDIAN Heart Registry. We sought to determine any impact on mortality outcomes as reported in the registry.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/4913

ORAL PRESENTATION: Impact of the 2018 UNOS Allocation Change on Severe Primary Graft Dysfunction: A Report from the International Consortium on PGD

  • Research collaborator: Shelley Hall, MD

  • Time: 5:12-5:16 p.m. CEST

  • Abstract/Study Purpose: : In 2018, the allocation system for heart transplantation (HT) in the US was changed to decrease waitlist times for the sickest candidates. Prior studies have suggested that this change resulted in the transplantation of sicker recipients, with an increase in recipients bridged with temporary MCS. We investigated whether the allocation change has impacted the prevalence of severe primary graft dysfunction (PGD).

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/4203

ORAL PRESENTATION: Organ Care System Heart Perfusion (OHP) Registry Annual Report – DCD Heart Transplants Clinical Outcomes

  • Research collaborator: Dan Meyer, MD

  • Time: 5:18-5:22 p.m. CEST

  • Abstract/Study Purpose: Organ Care System Heart Perfusion (OHP) registry was created to collect donor/recipient's characteristics and post-transplant outcomes for all OCS heart transplant cases in the real-world setting in the US. We are reporting early clinical outcomes from the DBD heart transplants cohort of the OHP registry.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/4917

SATURDAY, APRIL 13, 2024

SYMPOSIUM SESSION: How to Implement a Systemic Strategy to Promote and Assess Myocardial Recovery

  • Presenter: Cesar Guerrero-Miranda, MD

  • Time: 11:30-11:42 a.m. CEST

  • Abstract/Study Purpose: Myocardial recovery with or without an LVAD needs an organized effort in identifying patients, promoting recovery, and appropriately assessing the timing of readiness for explant.

  • For More Information: https://www.abstractsonline.com/pp8/#!/11008/presentation/3572

© 2024 Baylor Scott & White Health. All Rights Reserved.
Privacy and Patient Rights Terms of Use Notice of Non-Discrimination
3500 Gaston Ave., Dallas, TX 75246-2017 | 1.844.BSW.DOCS (1.844.279.3627)